Skip to search formSkip to main contentSkip to account menu

VEGFR2-targeted Contrast Agent BR55

Known as: BR55 
A lipopeptide-based, vascular endothelial growth factor receptor 2 (VEGRF2) -targeted contrast agent with the property of molecular imaging of… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
PURPOSE To investigate the ability of vascular endothelial growth factor receptor type 2 (VEGFR2)-targeted ultrasonographic (US… 
Highly Cited
2011
Highly Cited
2011
ObjectivesTo characterise clinically translatable long-circulating (BR38) and VEGFR2-targeted (BR55) microbubbles (MB) and to… 
2001
2001
MoAbs against tumour‐associated antigens (TAA) may be useful for the treatment of colorectal cancer. Since an increased… 
Highly Cited
2000
Highly Cited
2000
Peptides may substitute for carbohydrate antigens in carbohydrate-specific immunological reactions. Using the recognition… 
1999
1999
Monoclonal antibodies (MAb) specific for tumor-associated antigens (TAA) can induce an immunological cellular attack of tumor… 
1996
1996
The murine monoclonal antibody BR55-2 is directed against the tumor-associated antigen Lewis Y oligosaccharide. The Lewis Y core… 
1991
1991
IgG3 murine MAb BR55-2 is directed against adenocarcinoma associated Y oligosaccharide. Isotype IgG1, IgG2b and IgG2a switch… 
1990
1990
Isotype switch variants of the IgG3 secreting hybridoma BR55-2 were developed with gamma 1, gamma 2b and gamma 2a heavy chains… 
1989
1989
Immunohistochemical analysis with a monoclonal antibody, anti-BR55-2, was carried out on 163 tumors with their adjacent normal…